 Lupus anticoagulant inhibition vitro prostacyclin release thrombosis-prone subset patients PURPOSE effect lupus anticoagulant-containing sera endothelial prostacyclin generation basal thrombin stimulation Subsets patients arterial venous thrombosis respect quantitation antiphospholipid antibody effects prostacyclin production PATIENTS METHODS Serum antiphospholipid antibodies patients immunologic enzyme-linked immunosorbent assay kinetic anticoagulant assays Cultured human endothelial cells normal serum release prostacyclin radioimmunoassay supernatants Release absence presence secretagogue thrombin U/mL interassay variation clinical laboratory variables RESULTS normal prostacyclin response increase thrombin U/mL production Patients history arterial thrombosis Group IgG anticardiolipin antibody titers OD prolonged kaolin times seconds prostacyclin response Patients venous thrombosis Group titers intermediate clotting times seconds impaired prostacyclin responses Patients history thrombosis Group low antibody titers times seconds normal prostacyclin responses Patient serum basal arachidonate-induced prostacyclin production Group platelet counts Group Group similar age associated diagnoses CONCLUSIONS Inhibition prostacyclin responses serum patients lupus anticoagulants likely present patients high IgG anticardiolipin antibodies strong lupus anticoagulants low platelet counts recent arterial thrombosis